Cellular Biomedicine Group, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company announced in the following press release that, ” In addition to the safety and efficacy being demonstrated in clinical trials for the autologous ReJoin® therapy, the safety profile of allogeneic stem cell therapies in humans has been documented, and animal model studies conducted by the Company have also provided preliminary evidence of efficacy of allogeneic adipose derived and expanded mesenchymal progenitor cells for treatment of KOA.” Read the full article.
Cellular Biomedicine Group, Inc. is a biomedicine company. It engages in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. The company operates through Biomedicine segment is in development stage, conducting research and development activities to commercialize stem cell and immune cell therapeutics, related tools and products. Cellular Biomedicine Group was founded in 2009 and is headquartered in Palo Alto, CA. [Source: MarketWatch]
Company Website: http://www.cellbiomedgroup.com